overall survival

基本解釋

Obviously, the most important endpoint is overall survival.
顯然，最重要的終點(diǎn)是總體生存率。
Overall survival after two years was similar among both groups—88% on the drug versus 80% on placebo.
但是兩組患者兩年后的總存活率相似，服藥組為88％，服用安慰劑組為80％。
As noted, however, no significant difference in overall survival was seen between the groups, with a median survival period for each of about 26 months.
然而，正如已經(jīng)提到的，在各組之間沒有看到總體存活率的顯著性差異，中值存活期分別為約26個(gè)月。

"Women who had their ovaries removed had a decrease in the risk of breast cancer, a decrease in the risk of ovarian cancer and,in addition,they were less likely to die of breast cancer, less likely to die of ovarian cancer and also had an improvement in their overall survival."

The analysis of overall survival (OS), a key secondary endpoint of the study, is event driven.
FORBES: Modified Cold Sore Virus Shrinks Melanoma Tumors, Amgen Says
Both Xtandi and Zytiga, which are pills, have similar overall survival benefit relative to placebo, and quality-of-life data.
FORBES: Connect
Still, given the lack of an overall survival benefit, it might stay in the high 50s for some time.
FORBES: Amgen Drug Prevents Prostate Cancer From Spreading To Bone

總生存率
The 3-year overall survival rate was 66.7%.
3年總生存率是66.7%。
總生存期
However, cisplatin-based therapy showed a trend to benefit in TP53 wild type and to be harmful in TP53 mutated patients (P =0.18 for Overall Survival (OS) and P =0.13 for Disease Free Survival (DFS).
但是,存在一種趨勢(shì):順鉑輔助化療有利于TP53野生型患者的生存,而有害于TP53突變型患者的生存(P=0.18總生存期和P=0.13無病生存期)。
總體存活
In the multivariate analysis,cytology classification, histological type were prognostic factors for local relap se and cervical invasion was prognostic factor for overall survival.
Cox多變量回歸分析顯示,細(xì)胞學(xué)分級(jí)、組織學(xué)類型與子宮內(nèi)膜癌的復(fù)發(fā)有關(guān),宮頸是否侵犯與總體存活有關(guān)。